INTRIGUE: a randomized, open-label, phase 3 study evaluating the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumors previously treated with imatinib

被引：0

作者：

Bauer, S. ^{[1
,2
]}

Jones, R. L. ^{[3
,4
]}

Gelderblom, H. ^{[5
]}

George, S. ^{[6
]}

Schoeffski, P. ^{[7
]}

Von Mehren, M. ^{[8
]}

Zalcberg, J. ^{[9
,10
]}

Kang, Y. K. ^{[11
]}

Razak, A. A. ^{[12
]}

Trent, J. ^{[13
]}

Attia, S. ^{[14
]}

Le Cesne, A. ^{[15
]}

Su, Y. ^{[16
]}

Meade, J. ^{[16
]}

Wang, T. ^{[16
]}

Sherman, M. L. ^{[16
]}

Ruiz-Soto, R. ^{[16
]}

Blay, J. Y. ^{[17
]}

Heinrich, M. C. ^{[18
,19
]}

机构：

[1] Univ Duisburg Essen, Sarcoma Ctr, West German Canc Ctr, Univ Hosp Essen,Med Oncol, Partner Site Univ Hosp Essen, Essen, Germany

[2] German Canc Consortium DKTK, Med Oncol, Partner Site Univ Hosp Essen, Essen, Germany

[3] Royal Marsden NHS Fdn Trust, Sarcoma Unit, London, England

[4] Inst Canc Res, Sarcoma Unit, London, England

[5] Leiden Univ Med Ctr, Leiden, Netherlands

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Monash Univ, Med Oncol, Melbourne, Australia

[10] Alfred Hlth, Med Oncol, Melbourne, Australia

[11] Univ Ulsan, Asan Med Ctr, Seoul, South Korea

[12] Princess Margaret Canc Ctr, Toronto Sarcoma Program, Toronto, ON, Canada

[13] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[14] Mayo Clin, Jacksonville, FL USA

[15] Gustave Roussy, Villejuif, France

[16] Deciphera Pharmaceut LLC, Waltham, MA USA

[17] Ctr Leon Berard, Lyon, France

[18] Portland VA Hlth Care Syst, Portland, OR USA

[19] Knight Canc Inst, Portland, OR USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V870

引用

页码：263 / 263

页数：1

共 50 条

[1] INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
不详
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
[2] Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Bauer, Sebastian
Jones, Robin L.
Blay, Jean-Yves
Gelderblom, Hans
George, Suzanne
Schoeffski, Patrick
von Mehren, Margaret
Zalcberg, John R.
Kang, Yoon-Koo
Razak, Albiruni Abdul
Trent, Jonathan
Attia, Steven
Le Cesne, Axel
Su, Ying
Meade, Julie
Wang, Tao
Sherman, Matthew L.
Ruiz-Soto, Rodrigo
Heinrich, Michael C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3918 - +
[3] Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
Li, Jian
Zhang, Jun
Zhang, Yanqiao
Qiu, Haibo
Zhou, Yanbing
Zhou, Yongjian
Zhang, Xinhua
Zhou, Ye
Zhu, Yuping
Li, Yong
Wang, Ming
Shen, Kuntang
Tao, Kaixiong
Wu, Xin
Wang, Haijiang
Zhang, Bo
Ling, Jiayu
Ye, Yingjiang
Wu, Xingye
Qu, Hongyan
Ma, Yue
Jiao, Xuelong
Zheng, Hualong
Jin, Jiejie
Liu, Zhuo
Tan, Ming
Fang, Yong
Zhang, Peng
Zhang, Nan
Lei, Cheng
Cai, Zhaolun
Liang, Bin
Peng, Zhangyan
Huang, Zhao
Dong, Juan
Shen, Lin
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 196
[4] Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib
Nemunaitis, John
Bauer, Sebastian
Blay, Jean-Yves
Choucair, Khalil
Gelderblom, Hans
George, Suzanne
Schoffski, Patrick
von Mehren, Margaret
Zalcberg, John
Achour, Haroun
Ruiz-Soto, Rodrigo
Heinrich, Michael C.
[J]. FUTURE ONCOLOGY, 2020, 16 (01) : 4251 - 4264
[5] Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, openlabel study in China.
Li, Jian
Zhang, Jun
Zhang, Yanqiao
Qiu, Haibo
Zhou, Yanbing
Zhou, Yongjian
Zhang, Xinhua
Zhou, Ye
Zhu, Yuping
Li, Yong
Wang, Ming
Shen, Kuntang
Tao, Kaixiong
Wu, Xin
Wang, Haijiang
Zhang, Bo
Ling, Jiayu
Ye, Yingjiang
Dong, Juan
Shen, Lin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 803 - 803
[6] INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11+17/18 mutations.
Zalcberg, John Raymond
Blay, Jean-Yves
Chi, Ping
Jones, Robin Lewis
Serrano, Cesar
Somaiah, Neeta
Reichmann, William
Sprott, Kam
Cox, Paulina
Sherman, Matthew L.
Ruiz-Soto, Rodrigo
Heinrich, Michael C.
Bauer, Sebastian
George, Suzanne
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS767 - TPS767
[7] INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11+17 and/or 18 mutations
George, Suzanne
Blay, Jean-Yves
Chi, Ping
Jones, Robin Lewis
Serrano, Cesar
Somaiah, Neeta
Reichmann, William
Sprott, Kam
Achour, Haroun
Sherman, Matthew L.
Ruiz-Soto, Rodrigo
Heinrich, Michael C.
Bauer, Sebastian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial
Symcox, Marina
Jones, Robin L.
[J]. FUTURE ONCOLOGY, 2023, 19 (36) : 2383 - 2393
[9] Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study.
Gelderblom, Hans
Jones, Robin Lewis
Blay, Jean-Yves
George, Suzanne
Schoffski, Patrick
von Mehren, Margaret
Zalcberg, John Raymond
Kang, Yoon-Koo
Razak, Albiruni Ryan Abdul
Trent, Jonathan C.
Attia, Steven
Le Cesne, Axel
Harrow, Brooke
Becker, Claus
Wang, Tao
Sherman, Matthew L.
Ruiz-Soto, Rodrigo
Heinrich, Michael C.
Bauer, Sebastian
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Overall survival and long-term safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Final analyses from INTRIGUE.
Zalcberg, John Raymond
Jones, Robin Lewis
Blay, Jean-Yves
George, Suzanne
Gelderblom, Hans
Schoeffski, Patrick
von Mehren, Margaret
Kang, Yoon-Koo
Razak, Albiruni Ryan Abdul
Trent, Jonathan C.
Attia, Steven
Le Cesne, Axel
Davis, Erika
Achour, Haroun
Sherman, Matthew L.
Ruiz-Soto, Rodrigo
Bauer, Sebastian
Heinrich, Michael C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 748 - 748

← 1 2 3 4 5 →